50
Participants
Start Date
May 15, 2024
Primary Completion Date
May 15, 2028
Study Completion Date
December 15, 2028
Systemic therapy
"Atezolizumab-Bevacizumab every 3 weeks until progression or side effects in combination with Standardized immunosuppressive treatment:~Tacrolimus (objective 5-7 ng/ml) Mycophenolate Mofetil 1000 mg per day Corticosteroids at least 5 mg per day Everolimus will be continued if already started before the inclusion (objective 5-7 ng/ml). If everolimus has not been started prior to inclusion, do not start it, but adopt the following protocol: corticoids + Tacrolimus + Cellcept."
Assistance Publique - Hôpitaux de Paris
OTHER